High Throughput Technologies to Drive Breast Cancer Patients to Specific Phase I/II Trials of Targeted Agents
Observational
Observational Model: Cohort, Time Perspective: Prospective
number of patients included in early phase trials evaluating targeted drugs
To use whole genome / integrated biology approach to drive patients in early clinical trials. The goal is to include at least 30% of the patients in a clinical trial evaluating targeted agent, according to the molecular alteration detected on high throughput technologies
one year after obtaining the molecular profile
No
Fabrice André, MD phD
Principal Investigator
Institut Gustave Roussy, Villejuif, France
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
GRT01/0710 SAFIR-01
NCT01414933
May 2011
May 2017
Name | Location |
---|